Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries
Our study showed that although guidelines recommend the continued use of GnRH analogues in men with CRPC, a small proportion of men discontinue, the reasons for which are not fully understood. Further research is needed to explore potential contributing factors, such as differences in clinical practices, patient characteristics, or health care system across the countries studied.
Authors
- N. Lumen
- Mieke Van Hemelrijck (ORCID: https://orcid.org/0000-0002-7317-0858)
- Lucie‐Marie Scailteux (ORCID: https://orcid.org/0000-0001-7047-9107)
- Maria J. Monroy‐Iglesias (ORCID: https://orcid.org/0000-0003-2417-3275)
- G. Corrao
- A. Shamseddine
- C. Van Praet
- Gincy George (ORCID: https://orcid.org/0000-0003-0605-5507)
- M. Charafeddine
- B.A. Jereczek-Fossa
- D. Enting
- H. Garmo
- Giulia Marvaso (ORCID: https://orcid.org/0000-0002-5339-8038)
- L. Chehade
- P. Stattin
- F. Balusson
- I.F. Lissbrant
Institutions
- National Academy of Medicine (US)
- Uppsala University Hospital (SE)
- Inserm (FR)
- University of Milan (IT)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Sahlgrenska University Hospital (SE)
- Ghent University Hospital (BE)
- London Cancer (GB)
- American University of Beirut Medical Center (LB)
- Institut de Recherche en Santé, Environnement et Travail (FR)
- European Institute of Oncology (IT)
- University of Gothenburg (SE)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100122
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00